摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tert-butyl 4-(((5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)oxy)methyl)-4-fluoropiperidine-1-carboxylate | 1610417-17-8

中文名称
——
中文别名
——
英文名称
tert-butyl 4-(((5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)oxy)methyl)-4-fluoropiperidine-1-carboxylate
英文别名
tert-butyl 4-[(5-amino-4-methyl-1-phenylpyrazol-3-yl)oxymethyl]-4-fluoropiperidine-1-carboxylate
tert-butyl 4-(((5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)oxy)methyl)-4-fluoropiperidine-1-carboxylate化学式
CAS
1610417-17-8
化学式
C21H29FN4O3
mdl
——
分子量
404.485
InChiKey
CNDSNXUNLFGDTM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    29
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    82.6
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    tert-butyl 4-(((5-amino-4-methyl-1-phenyl-1H-pyrazol-3-yl)oxy)methyl)-4-fluoropiperidine-1-carboxylate(2-Cyclopropyl-5-(methoxymethyl)phenyl)methanamine(5-(methoxymethyl)-2-(trifluoromethoxy)phenyl)methanamine 以to give the title compound (33%)的产率得到tert-butyl 4-fluoro-4-(((5-(3-(5-(methoxymethyl)-2-(trifluoromethoxy)benzyl)ureido)-4-methyl-1-phenyl-1H-pyrazol-3-yl)oxy)methyl)piperidine-1-carboxylate
    参考文献:
    名称:
    N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
    摘要:
    式I的化合物或其立体异构体、互变异构体、药学上可接受的盐、溶剂化合物或前药,其中环A、环C、X、Ra、Rb、Rc、Rd和n的定义如本文所述,是TrkA激酶的抑制剂,可用于治疗可通过TrkA激酶抑制剂治疗的疾病,如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、Sjogren综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或盆腔疼痛综合征。
    公开号:
    US20160272592A1
点击查看最新优质反应信息

文献信息

  • [EN] N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE N-(ARYLALKYLE)-N'-PYRAZOLYLE-URÉE, DE THIOURÉE, DE GUANIDINE ET DE CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2014078331A1
    公开(公告)日:2014-05-22
    Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
    公式I的化合物或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药,其中环A、环C、X、Ra、Rb、Rc、Rd和n如本文所述定义,是TrkA激酶的抑制剂,可用于治疗可以用TrkA激酶抑制剂治疗的疾病,如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或骨盆疼痛综合征。
  • [EN] N-(MONOCYCLIC ARYL),N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE N-ARYLE MONOCYCLIQUES, N'-PYRAZOLYL-URÉE, THIOURÉE, GUANIDINE ET CYANOGUANIDINE UTILES COMME INHIBITEURS DE TRKA KINASE
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2014078325A1
    公开(公告)日:2014-05-22
    Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
    化合物的公式(I)或其立体异构体、互变异构体、或其药学上可接受的盐、溶剂合物或前药,其中环A、环C和X如本文所定义,是TrkA激酶的抑制剂,并且在治疗可以用TrkA激酶抑制剂治疗的疾病中具有用处,如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、干燥综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或盆腔疼痛综合征。
  • N-(MONOCYCLIC ARYL),N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
    申请人:ARRAY BIOPHARMA INC.
    公开号:US20160280692A1
    公开(公告)日:2016-09-29
    Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
  • US9790210B2
    申请人:——
    公开号:US9790210B2
    公开(公告)日:2017-10-17
  • US9969694B2
    申请人:——
    公开号:US9969694B2
    公开(公告)日:2018-05-15
查看更多